Melanotan II
The "tanning peptide" — a synthetic α-MSH analog whose effects, and risks, follow directly from which receptors it presses.
What is Melanotan II?
The short version. Melanotan II is a lab-made copy of one of the body's own signals. Your body makes a hormone called α-MSH (alpha-melanocyte-stimulating hormone) that, among other things, tells skin cells to produce pigment. Melanotan II is a synthetic, sturdier version of that signal — which is how it earned the nickname "the tanning peptide."
Where it comes from. It was built in the 1980s as part of a research effort to create a more stable, longer-lasting α-MSH. The natural hormone breaks down fast; researchers looped it into a cyclic peptide that resists breakdown and binds more strongly, producing a far more potent melanocortin signal.
The one thing that explains everything. α-MSH doesn't act on a single target — it works through a family of receptors, MC1R through MC5R, each in different tissues doing different jobs. Melanotan II is a non-selective agonist: it binds MC1R, MC3R, MC4R and MC5R. Think of it as a master key cut to open several doors at once, not just one. That single fact explains the tanning, the other effects, and the risks alike.
How Melanotan II Works
The big-picture answer first. Picture the melanocortin receptors as switches in different rooms of the body. Melanotan II is a key that fits several of them — and which switches it flips, and where, is the whole story.
The pigment switch (MC1R). In the skin, it activates MC1R on melanocytes, the pigment cells. Research shows this drives production of eumelanin, the dark protective pigment — the mechanism behind its tanning reputation. It turns up the dimmer on the skin's own pigment factory.
The central switches (MC4R). It also reaches MC4R, active in the brain. Research has linked MC4R activation to two distinct effects seen in human trials: changes in appetite, and central pathways involved in sexual arousal. It's the same receptor family that the more selective PT-141 was later built around.
Why the side effects are part of the package. Because it's non-selective, the receptors behind nausea, flushing and the central effects get pressed alongside the pigment one. Research treats these as inseparable from the mechanism — not a contaminant, just the same key opening extra doors.
Where the Research Focuses
The pigment story — how MC1R activation drives eumelanin production. The original and best-characterised part of the Melanotan II picture.
The brain-side receptor. Human studies have examined MC4R's role in appetite and in central arousal pathways — the effects that make Melanotan II more than a pigment compound.
A favourite research contrast: Melanotan II's non-selectivity versus the more selective afamelanotide (MT-I) and bremelanotide (PT-141), built to isolate single effects.
An active area: case reports linking unregulated use to melanoma, mole changes, and systemic events — studied precisely because the mechanism touches the cells involved in skin cancer.
The Honest Risk Picture
Melanotan II is one of the few compounds in this library where the risks matter as much as the mechanism — so we'll give them to you straight. It has never been approved as a drug anywhere, and has no completed efficacy trials. The published literature includes case reports linking unregulated Melanotan II use to cutaneous and mucosal melanoma and to changes in existing moles — a signal that makes biological sense, since the compound activates the very cells involved in melanoma. Human studies and case reports also describe nausea, facial flushing, spontaneous erections, and rarer serious events. None of this is small print: it's the honest other half of a genuinely potent molecule.
Technical Specifications
Frequently Asked Questions
Research use only. Not for human or veterinary use.
Compiled by the Southern Pacific Labs research team. Last updated June 2026.
Published References
- Dorr RT, Lines R, Levine N, et al. “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.” Life sciences, 1996. PubMed
- Wessells H, Levine N, Hadley ME, et al. “Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.” International journal of impotence research, 2000. PubMed
- Hadley ME, Dorr RT. “Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.” Peptides, 2006. PubMed
- Hjuler KF, Lorentzen HF. “Melanoma associated with the use of melanotan-II.” Dermatology (Basel, Switzerland), 2014. PubMed
Browse all Melanotan II research on PubMed →
Related Research Guides
More in Melanocortin Research
The selective melanocortin relative, developed toward the MC4R arousal pathway.
Read guide →Selective MC1R AgonistThe selective sibling — MC1R-preferential, and an approved photoprotection drug.
Read guide →Anti-Inflammatory TripeptideA C-terminal fragment of the same α-MSH parent hormone.
Read guide →